Insider Trading Alert - CVT, ARAY And AMGN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 3, 2014, 112 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $402.00 to $128,403,039.00.

Highlighted Stocks Traded by Insiders:

Cvent (CVT) - FREE Research Report

Ludwig Brian, who is SVP, Sales at Cvent, sold 485 shares at $27.00 on Dec. 3, 2014. Following this transaction, the SVP, Sales owned 125,336 shares meaning that the stake was reduced by 0.39% with the 485-share transaction.

The shares most recently traded at $27.09, up $0.09, or 0.33% since the insider transaction. Historical insider transactions for Cvent go as follows:

  • 4-Week # shares sold: 22,000
  • 12-Week # shares bought: 13,000
  • 12-Week # shares sold: 28,970
  • 24-Week # shares bought: 13,000
  • 24-Week # shares sold: 51,940

The average volume for Cvent has been 189,700 shares per day over the past 30 days. Cvent has a market cap of $1.1 billion and is part of the technology sector and computer software & services industry. Shares are down 22.67% year-to-date as of the close of trading on Tuesday.

Cvent, Inc. provides a cloud-based enterprise event management platform with solutions for both sides of the events and meetings value chain primarily in North America. The company has a P/E ratio of 270.0. Currently, there is 1 analyst who rates Cvent a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVT - FREE

TheStreet Quant Ratings rates Cvent as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Cvent Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Accuray (ARAY) - FREE Research Report

Londy Kelly, who is EVP Chief Commercial Officer at Accuray, sold 2,273 shares at $6.62 on Dec. 3, 2014. Following this transaction, the EVP Chief Commercial Officer owned 179,786 shares meaning that the stake was reduced by 1.25% with the 2,273-share transaction.

Nouri Alaleh, who is SVP, General Counsel & at Accuray, sold 268 shares at $6.62 on Dec. 3, 2014. Following this transaction, the SVP, General Counsel & owned 73,979 shares meaning that the stake was reduced by 0.36% with the 268-share transaction.

The shares most recently traded at $6.74, up $0.12, or 1.78% since the insider transaction. Historical insider transactions for Accuray go as follows:

  • 4-Week # shares bought: 100,000
  • 4-Week # shares sold: 7,000
  • 12-Week # shares bought: 100,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 100,000
  • 24-Week # shares sold: 7,000

The average volume for Accuray has been 877,300 shares per day over the past 30 days. Accuray has a market cap of $517.7 million and is part of the health care sector and health services industry. Shares are down 23.56% year-to-date as of the close of trading on Tuesday.

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. Currently, there are 4 analysts who rate Accuray a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARAY - FREE

TheStreet Quant Ratings rates Accuray as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full Accuray Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Amgen (AMGN) - FREE Research Report

De Carbonnel Francois, who is Director at Amgen, sold 3,000 shares at $168.01 on Dec. 3, 2014. Following this transaction, the Director owned 19,159 shares meaning that the stake was reduced by 13.54% with the 3,000-share transaction.

The shares most recently traded at $168.07, up $0.06, or 0.03% since the insider transaction. Historical insider transactions for Amgen go as follows:

  • 4-Week # shares bought: 894
  • 4-Week # shares sold: 14,000
  • 12-Week # shares bought: 894
  • 12-Week # shares sold: 14,000
  • 24-Week # shares bought: 894
  • 24-Week # shares sold: 14,000

The average volume for Amgen has been 4.0 million shares per day over the past 30 days. Amgen has a market cap of $126.6 billion and is part of the health care sector and drugs industry. Shares are up 48.39% year-to-date as of the close of trading on Tuesday.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. The stock currently has a dividend yield of 1.47%. The company has a P/E ratio of 26.2. Currently, there are 7 analysts who rate Amgen a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMGN - FREE

TheStreet Quant Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, solid stock price performance, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI